Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill aims to stop kidney stones before they start

NCT ID NCT06932146

Disease control Sponsor: Lilac Therapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called LLX-424 in 51 adults who have had kidney stones before. The drug works by blocking an enzyme that makes oxalate, a key ingredient in most kidney stones. Participants took the drug or a placebo daily for 8 weeks to see if it safely lowers oxalate levels in urine.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LLX-424 (a glycolate oxidase inhibitor taken as a tablet)
What this could lead to
If it works, this could lead to a new daily pill that helps prevent calcium oxalate kidney stones from forming.
What could go wrong
This is a small, early-phase trial focused on safety and lab markers, not stone prevention. The drug may not reduce stones in real life or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

51 people

The number who actually took part.

Started

Mar 2025

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * History of kidney stones documented in medical records * 24-hour urine oxalate excretion * Body mass index 18.5 to 38 kg/m2 inclusive * Estimated glomerular filtration rate ≥ 60 mL/min/1.73m2 Exclusion Criteria: * History or medical record evidence of kidney stones that are not calcium oxalate * Unstable kidney function * Spot urine protein to creatinine ratio ≥ 1 mg/mg at screening * History of kidney transplantation * Hemoglobin A1c \> 9.5% at screening * History of enteric hyperoxaluria, intestinal malabsorption, bariatric surgery, intestinal surgery, inflammatory bowel disease * History or evidence of cirrhosis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Kidney stones are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Kidney Calculi nephrolithiasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Kidney stones

Contacts and locations

Locations

  • Clinical Research Site #1

    San Antonio, Texas, 78217, United States

  • Clinical Research Site #2

    Saint Paul, Minnesota, 55114, United States

  • Clinical Research Site #3

    Springfield, Missouri, 65802, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.